GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
==== Antidepressants ==== Some antidepressants have hypnotic and/or sedative effects. These include the serotonin antagonist and reuptake inhibitor (SARI) trazodone, tricyclic antidepressants (TCAs) such as amitriptyline, doxepin, and trimipramine, and tetracyclic antidepressants (TeCAs) like mirtazapine and mianserin. These agents produce their hypnotic and sedative effects via multiple mechanisms of action that may include histamine H1 receptor antagonism, serotonin 5-HT2A receptor antagonism, and α1-adrenergic receptor antagonism. Some hypnotic antidepressants, such as trazodone and mirtazapine, have been shown to enhance slow wave sleep, which may be due to serotonin 5-HT2A receptor antagonism.
=== Pharmacodynamics === Teicoplanin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis. It binds to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the peptidoglycan precursor, preventing the transpeptidation reaction necessary for cell wall cross-linking. This binding also interferes with the polymerization of peptidoglycan, ultimately leading to cell death. In addition to its binding to the D-Ala-D-Ala terminus, teicoplanin may also interact with the lipid II substrate in the bacterial cell membrane through its hydrophobic tail. This interaction could facilitate the antibiotic's proximity to the nascent peptidoglycan, enhancing its inhibitory effect. However, this mechanism has not been fully confirmed.
Vasoactive intestinal peptide (VIP; PHM27) Pituitary adenylate cyclase activating peptide (PACAP) Peptide PHI 27 (peptide histidine isoleucine 27) Growth hormone releasing hormone (GHRH) 1-24 Glucagon Secretin
Sources: en.wikipedia.org
== Synthetic monomers == Ethylene gas (H2C=CH2) is the monomer for polyethylene. Other modified ethylene derivatives include: tetrafluoroethylene (F2C=CF2) which leads to Teflon vinyl chloride (H2C=CHCl) which leads to PVC styrene (C6H5CH=CH2) which leads to polystyrene Epoxide monomers may be cross linked with themselves, or with the addition of a co-reactant, to form epoxy BPA is the monomer precursor for polycarbonate Terephthalic acid is a comonomer that, with ethylene glycol, forms polyethylene terephthalate. Dimethylsilicon dichloride is a monomer that, upon hydrolysis, gives polydimethylsiloxane. Ethyl methacrylate is an acrylic monomer that, when combined with an acrylic polymer, catalyzes and forms an acrylate plastic used to create artificial nail extensions
==== Laos and Cambodia ==== Separate accords were signed by the signatories with the Kingdom of Laos and the Kingdom of Cambodia in relation to Laos and Cambodia respectively. Following the terms of the agreement, Laos would be governed by the Royal Lao Government, while Cambodia would be ruled by the royal court of Norodom Sihanouk. Despite retaining its monarchy, the agreement also allowed for "VWP-affiliated Laotian forces" to run the provinces of Xam Neua and Phongsaly, further expanding North Vietnamese influence within Indochina. The Viet Minh and North Vietnamese never really withdrew from the border areas of Laos and the Pathet Lao continued to operate almost as a branch organization of the Viet Minh. Two months after the conference, the North Vietnamese formed Group 100 with headquarters at Na Mèo. Due to the agreement, communist forces in Cambodia would remain out of power. With this backdrop around a thousand of UIF cadres left for Vietnam along with the departing Viet Minh forces, on Polish ships provided by the ICSC on the Mekong river.
Proteins can be engineered to improve the chance of successful protein crystallization. A common way is by trimming the recombinant construct to remove N- and C- terminal parts, which are frequently disordered or poorly structured ("high entropy"). Surface entropy reduction entails replacing surface residue clusters with high conformational entropy (usually lysine, glutamate, and glutamine) with alanines. In a similar vein, replacing lysine with arginine in bulk has proven useful. It is also possible to engineer in crystal contacts by mutating residues. An even more advanced method involves the use of "chaperone" proteins known to be more crystallizable. This can be achieved by designing a fusion protein consisting of the protein with unknown structure and a protein domain known to crystalize well. The interaction in question can also be intermolecular, for example between the candidate protein and some antibody Fab fragments selected to bind tightly to the protein, or between a candidate-maltose-binding protein (MBP) fusion and a protein specifically designed to bind MBP. Many methods for protein engineering require some forward knowledge of protein structure, either simply knowing what residues are surface or buried or knowing the full tertiary structure. Modern protein structure prediction tools are largely sufficient. It is also possible to predict the result of crystallization using these methods. Cystine residues on the surface tend to cause trouble for recombinant protein production by causing aggregation. They can be replaced with alanines.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.